Equinor ASA (0M2Z)
London Exchange · UK · prices in NOK · close of 23 Oct 2026
Key indicators
| Last close | NOK 452.65 |
|---|---|
| 52-week range | 226.30 – 452.65 |
| Return, 1 month / 3 months | +12.1% / +15.9% |
| Return, 1 year / 3 years | +90.9% / +43.3% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 36.8% |
| Worst drawdown (1 year) | -25.9% |
| Average daily value traded | 160.82M NOK |
| Dividend yield | 3.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Equinor ASA is an energy company based in Norway that produces oil and natural gas, chiefly from fields off the Norwegian coast, and supplies these fuels to customers in Europe and other markets. It also operates refineries and processing plants and is involved in offshore wind and other low-carbon energy projects. The Norwegian state holds a majority stake in the company, which serves industrial buyers, utilities and households through its energy trading and marketing activities.
The shares are listed on the London Exchange in UK under the code 0M2Z, and the price on this page is in Norwegian kroner (NOK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Equinor ASA (0M2Z) trades on the London Exchange in UK. It last closed at NOK 452.65 on 23 October 2026.
Its price-based Market X-Ray is 79 out of 100 (a strong price profile), ranking 71 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 90.9% and over the last three months it rose 15.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 94 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 31.3% | ||
| From 52-week high | 0.0% | ||
| Momentum | 88 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 15.9% | ||
| 6-month return | 29.1% | ||
| 12-month return, skipping the last month | 70.2% | ||
| Stability (higher is calmer) | 52 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.9% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 160.82M NOK | ||
| Zero-volume days | 0.0% | ||
| Income | 70 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.2% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.3% |
|---|---|
| 1 month | +12.1% |
| 3 months | +15.9% |
| 6 months | +29.1% |
| 1 year | +90.9% |
| 3 years | +43.3% |
| 5 years | +147.9% |
Signals
| 50-day / 200-day average | 408.99 / 344.83 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.71 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Aug 2026 | NOK 3.6882 |
| 13 May 2026 | NOK 3.6041 |
| 16 Feb 2026 | NOK 3.5249 |
| 13 Nov 2025 | NOK 3.7324 |
| 18 Aug 2025 | NOK 3.7740 |
| 15 May 2025 | NOK 3.8215 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.